Back to search

Boston University

The role of SPAK (STK39) kinase in the progression of metabolic dysfunction-associated steatohepatitis (MASH) induced by a high-fat, high-fructose diet mouse model

Abstract

dc:description.abstract

Metabolic dysfunction-associated fatty liver disease (MAFLD) and its aggressive progressive form, Metabolic dysfunction-associated steatohepatitis (MASH), represent a rapidly growing global health burden. MASH is histologically characterized by hepatic steatosis, lobular inflammation, hepatocyte ballooning, and fibrosis, and can progress to cirrhosis and hepatocellular carcinoma if left untreated. The pathophysiology of MASH involves complex interactions among metabolic dysregulation, oxidative stress, and chronic inflammatory signaling. While many molecular contributors to MASH have been identified, effective therapeutic targets remain limited. This study investigates the therapeutic potential of targeting SPAK kinase in attenuating MASH progression using a high-fat, high-fructose (HFHF) diet-induced mouse model. Wild-type (WT) and SPAK knockout (SPAK KO) mice across six experimental groups, encompassing young, aged, and diet-challenged conditions, were subjected to a comprehensive histological and immunofluorescence panel, with the central comparison focused on whether SPAK deletion attenuates HFHF diet-induced MASH pathology; young and aged chow-fed cohorts provided baseline and age-related context. Liver sections were evaluated using hematoxylin and eosin (H&E) staining for steatosis, ballooning, and lobular inflammation; Picrosirius Red (PSR) for fibrosis; Sudan 3 for neutral lipid accumulation; and immunofluorescence for CD68 (macrophage infiltration), SPAK kinase expression, Vimentin (stellate cell activation), Collagen 1a1 (extracellular matrix deposition), and Ly6G (neutrophil infiltration). This study establishes two central findings. First, hepatic SPAK expression increases progressively with both aging and HFHF diet-induced obesity, identifying SPAK as a stress-responsive kinase whose hepatic expression tracks with metabolic burden. Second, genetic deletion of SPAK confers broad protection against HFHF diet-induced MASH pathology: across the staining modalities quantified in this study, SPAK KO mice subjected to HFHF feeding exhibited consistently attenuated pathology relative to WT controls, including reduced steatosis, diminished inflammatory infiltration, and less extensive fibrosis. Together, these findings establish SPAK as a novel hepatic metabolic regulator and support its potential as a therapeutic target in MASH.

Degree

thesis:*
Name thesis:degree_name
Master of Science
Level thesis:degree_level
masters
Discipline thesis:degree_discipline
Nutrition and Metabolism
Grantor
Boston University
Year dc:date.issued
2026

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Joseph, Vanel
Advisors dc:contributor.advisor
  • Jiang, Zhen
  • Deeney, Jude

Subjects

dc:subject × 7

Rights

Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
https://hdl.handle.net/2144/53482

Chain of custody

source
Harvested from
Boston University
Base URL
open.bu.edu/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Joseph, Vanel. The role of SPAK (STK39) kinase in the progression of metabolic dysfunction-associated steatohepatitis (MASH) induced by a high-fat, high-fructose diet mouse model. masters thesis, Boston University, 2026. https://hdl.handle.net/2144/53482